DCT

2:18-cv-09655

Janssen Products LP v. DR Reddy's Laboratories Inc

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 2:18-cv-09655, D.N.J., 05/24/2018
  • Venue Allegations: Venue is alleged to be proper based on the New Jersey incorporation and principal places of business for Defendants Dr. Reddy’s Laboratories, Inc. and PharmaQ, Inc. For the foreign defendants, venue is alleged as proper in any judicial district.
  • Core Dispute: Plaintiff alleges that Defendants’ filing of an Abbreviated New Drug Application (ANDA) to market generic versions of the HIV drug PREZISTA® (darunavir) constitutes an act of infringement of three U.S. patents covering the drug’s pseudopolymorphic forms and methods of manufacturing a key chemical intermediate.
  • Technical Context: The technology concerns pharmaceutical chemistry, specifically stable crystalline forms of the HIV protease inhibitor darunavir and stereoselective, industrially scalable processes for synthesizing a critical component.
  • Key Procedural History: This Hatch-Waxman action was triggered by Defendants' submission of ANDA No. 21-1578 with a Paragraph IV certification. The complaint notes that the asserted patents have been the subject of previous infringement litigations against other generic manufacturers, which resulted in consent judgments in favor of the Plaintiff.

Case Timeline

Date Event
2001-09-10 ’015 Patent Priority Date
2002-05-16 ’987 Patent Priority Date
2004-03-31 ’408 Patent Priority Date
2006-10-24 ’015 Patent Issue Date
2009-09-29 ’408 Patent Issue Date
2013-08-27 ’987 Patent Issue Date
2018-04-13 DRL Paragraph IV Letter Date
2018-04-16 Janssen receives Paragraph IV Letter
2018-05-24 Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 8,518,987 - Pseudopolymorphic forms of a HIV protease inhibitor (Issued Aug. 27, 2013)

The Invention Explained

  • Problem Addressed: The patent's background describes the technical challenges in pharmaceutical formulation, where the physical form of a drug substance can significantly impact its stability, purity, and bioavailability. The implicit problem is the need to identify and characterize a stable, manufacturable solid form of the active pharmaceutical ingredient (API) darunavir for use in a final drug product (’987 Patent, col. 2:8-24).
  • The Patented Solution: The invention claims specific pseudopolymorphic forms—crystalline structures that incorporate solvent molecules (solvates) like water (hydrates) or ethanol (ethanolates)—of darunavir. The patent provides detailed characterization data for these forms, suggesting they possess the requisite physical properties for consistent and effective pharmaceutical manufacturing and therapeutic use (’987 Patent, Abstract; col. 3:1-10).
  • Technical Importance: The identification of a stable and reproducible crystalline form of an API is a critical step in drug development, as it ensures consistent dissolution rates and bioavailability, which are fundamental to patient safety and regulatory approval (’987 Patent, col. 2:20-41).

Key Claims at a Glance

  • The complaint alleges infringement of "one or more claims" without specifying which ones (Compl. ¶92). Independent claim 1 is representative:
    • A hydrate of the compound (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl (1S,2R)-3-[(4-aminophenyl) sulfonylamino]-1-benzyl-2-hydroxypropylcarbamate
    • in which the ratio of the compound to water is about 1:0.5 to about 1:3.

U.S. Patent No. 7,126,015 - Method for the Preparation of Hexahydro-furo-[2,3-b]furan-3-ol (Issued Oct. 24, 2006)

The Invention Explained

  • Problem Addressed: The patent addresses the challenge of synthesizing (3R,3aS,6aR)hexahydro-furo[2,3-b]furan-3-ol, a key chiral intermediate in the manufacture of darunavir, referred to as "bis-THF" in the complaint (Compl. ¶66). Prior art methods are described as unsuitable for large-scale production due to the use of expensive or hazardous reagents, extreme reaction temperatures, and inefficient purification steps, rendering them not "amenable to industrial scaling up" (’015 Patent, col. 2:1-11).
  • The Patented Solution: The patent discloses a novel, stereoselective method for preparing bis-THF that overcomes the limitations of prior art processes. The invention provides a synthetic pathway that begins with a readily available starting material (an O-protected glyceraldehyde) and proceeds through a series of reactions, including a key Nef reaction, to produce the desired intermediate in a manner suitable for industrial manufacturing (’015 Patent, Abstract; col. 2:46-60).
  • Technical Importance: The development of a safe, cost-effective, and scalable manufacturing process for a critical pharmaceutical intermediate is essential for making the final drug commercially viable and widely available (’015 Patent, col. 2:25-31).

Key Claims at a Glance

  • The complaint alleges infringement of "one or more claims" without specification (Compl. ¶112). Independent claim 1 covers a multi-step chemical synthesis:
    • A method for the synthesis of hexahydro-furo[2,3-b]furan-3-ol of formula (7),
    • starting from an intermediate of formula (1),
    • transforming said intermediate into a nitromethane derivative of formula (3),
    • subsequently transforming said derivative into a tetrahydrofuran derivative of formula (6),
    • and then transforming the intermediate of formula (6) into the final product of formula (7) by an intramolecular cyclisation reaction.

U.S. Patent No. 7,595,408 - Methods for the Preparation of (3R,3aS,6aR) Hexahydro-furo-[2,3-b]furan-3-ol (Issued Sep. 29, 2009)

  • Technology Synopsis: This patent discloses further improvements to the synthesis of the bis-THF intermediate. It describes a process that yields a specific, crystallizable methyl acetal intermediate, which allows for efficient purification and epimerization. This innovation reportedly increases the overall yield and diastereomeric purity of the final bis-THF product, enhancing its suitability for cost-effective industrial production (’408 Patent, Abstract; col. 4:1-10).
  • Asserted Claims: The complaint alleges infringement of "one or more claims" (Compl. ¶122). The patent includes independent method claims, such as claim 1.
  • Accused Features: The complaint alleges that Defendants intend to use the processes claimed in the ’408 Patent to prepare the bis-THF component required for the darunavir API in their ANDA Products (Compl. ¶¶66, 69).

III. The Accused Instrumentality

Product Identification

  • The accused instrumentalities are Defendants’ generic darunavir 600 mg and 800 mg tablets, for which ANDA No. 21-1578 was filed, and the processes used to manufacture the active pharmaceutical ingredient (API) for those products (Compl. ¶2).

Functionality and Market Context

  • The accused tablets are intended to be generic equivalents of Janssen's PREZISTA®, an HIV protease inhibitor indicated for the treatment of HIV infection (Compl. ¶¶2, 57-58). The complaint characterizes PREZISTA® as "highly successful," suggesting a significant commercial market for the accused generic products (Compl. ¶2). The infringement allegations against the '987 Patent target the final solid dosage form of the drug, while the allegations against the '015 and '408 patents target the manufacturing process for the "bis-THF" component, which the complaint identifies as an "essential component of darunavir" (Compl. ¶66). No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

The complaint does not provide claim charts or detailed, element-by-element infringement allegations for any of the patents-in-suit. Instead, it presents narrative infringement theories.

  • '987 Patent Infringement Theory: The complaint alleges on "information and belief" that the Defendants' ANDA Products will infringe one or more claims of the ’987 Patent (Compl. ¶92). This assertion appears to be based on an inference drawn from Defendants' alleged failure to provide product samples and analytical data, which Janssen requested to evaluate the crystalline form of the API (Compl. ¶¶90-91). The core theory is that the darunavir API in the ANDA Products possesses the claimed pseudopolymorphic structure.
  • '015 and '408 Patents Infringement Theory: The infringement allegations for these process patents are brought under 35 U.S.C. § 271(g), which prohibits the importation or sale of a product made by a process patented in the U.S. (Compl. ¶¶107, 117). The theory is inferential. Janssen alleges that it requested and received from Defendants only a "short, selectively redacted DMF excerpt that is insufficient to determine the process actually used" (Compl. ¶73). Janssen further alleges that the synthesis route described in that excerpt is "commercially infeasible" and that the only known commercially viable processes for producing the required bis-THF intermediate are those covered by its patents (Compl. ¶¶73-74). The complaint concludes that Defendants' refusal to provide complete manufacturing information is consistent with the conclusion that they are, in fact, using the patented processes (Compl. ¶77).
  • Identified Points of Contention:
    • Evidentiary Questions: For all three patents, a central dispute will likely be evidentiary. For the '987 Patent, the question is what analytical data (e.g., XRPD, TGA) will show about the crystalline form of the API in the ANDA product. For the '015 and '408 patents, the question is whether Janssen can prove, either through discovery or circumstantial evidence, the specific chemical process Defendants use to manufacture the bis-THF intermediate.
    • Technical Questions: A potential technical dispute for the '015 and '408 patents is whether the process described in Defendants' redacted documents is, as Janssen alleges, truly "commercially infeasible" (Compl. ¶73). This may become a subject of expert testimony regarding chemical process scalability and economics.

V. Key Claim Terms for Construction

  • The Term: "a hydrate... in which the ratio of the compound to water is about 1:0.5 to about 1:3" (from '987 Patent, claim 1).

    • Context and Importance: The definition of this term is dispositive for infringement of claim 1. The dispute may focus on the scope of "hydrate" and the range encompassed by the word "about." Practitioners may focus on this term because infringement will turn on whether analytical testing of the accused product shows a crystalline water-solvate that falls within this claimed ratio.
    • Intrinsic Evidence for Interpretation:
      • Evidence for a Broader Interpretation: The use of "about" suggests the patentee did not intend to be limited to the exact numerical endpoints. The specification's general discussion of pseudopolymorphs could be cited to argue for a meaning that includes related solvated forms (’987 Patent, col. 3:1-5).
      • Evidence for a Narrower Interpretation: The specification provides specific examples with detailed analytical data (e.g., TGA, DSC) for particular hydrates (’987 Patent, Example 1; FIG. 16). A party could argue that the term should be construed in light of these specific embodiments, limiting its scope to forms that are structurally and quantitatively consistent with those examples.

  • The Term: "a Nef reaction" (from '015 Patent, claim 2).

    • Context and Importance: This term defines a critical step in the asserted manufacturing process. Infringement may depend on whether the specific chemical transformation used by Defendants to convert a nitro-group to a carbonyl-group qualifies as a "Nef reaction."
    • Intrinsic Evidence for Interpretation:
      • Evidence for a Broader Interpretation: The specification notes that while the "classical procedure" for a Nef reaction involves a base followed by a strong acid, "Nef-conversions can be accomplished using a broad variety of oxidizing as well as reducing agents known in the art" (’015 Patent, col. 13:13-22; col. 14:64-67). This language may support a construction that is not limited to the classic acid/base protocol.
      • Evidence for a Narrower Interpretation: A party could argue the term should be limited by the specific reaction conditions detailed in the patent's working examples, which utilize the classical base/acid procedure (’015 Patent, col. 15:9-14).

VI. Other Allegations

  • Indirect Infringement: The complaint includes allegations of induced and contributory infringement for all patents (Compl. ¶¶ 102, 112, 122). The factual basis alleged is that the defendants "acted in concert" in the development, preparation, and filing of the ANDA and DMF (Compl. ¶80, 86).
  • Willful Infringement: Willfulness is alleged for the '015 and '408 patents (Compl. ¶¶ 114, 124). The complaint alleges that Defendants had both actual and constructive pre-suit notice of the patents, including through "judgments in Janssen's favor against other generic manufacturers in this Court" (Compl. ¶94).

VII. Analyst’s Conclusion: Key Questions for the Case

  • A core issue will be one of evidentiary proof: For the '987 patent, can Janssen demonstrate through analytical testing that the accused generic product contains the specific crystalline hydrate claimed? For the '015 and '408 process patents, can Janssen prove that the accused product is "made by" the patented process, particularly if direct evidence is not forthcoming from the Defendants?
  • A key technical question will be one of commercial reality: The infringement theory for the process patents appears to rest heavily on the allegation that alternative synthetic routes are "commercially infeasible." The case may therefore turn on expert testimony concerning the practical and economic viability of different methods for manufacturing the bis-THF intermediate at an industrial scale.
  • A central legal question will be one of willfulness: Given the complaint’s allegations that Defendants had pre-suit knowledge of the patents and their successful assertion against other parties, the court will likely examine whether Defendants' alleged conduct—including the filing of the ANDA and the purported withholding of technical information—was sufficiently egregious to support an enhancement of damages.
Loading Complaint